|Videos|December 27, 2022
Scynexis CEO talks recent ibrexafungerp approval
Author(s)Morgan Ebert
Marco Taglietti, MD, president and CEO of Scynexis, sits with Contemporary OB/GYN® to discuss the recent approval of ibrexafungerp (Brexafemme) for the reduction in incidence of recurrent vulvovaginal candidiasis.
Advertisement
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Daré Bioscience launches prescription-free vaginal probiotic capsule for microbiome support
2
Subfecundity, not IVF, linked to elevated neurodevelopmental risk in offspring
3
Psychological and urogenital menopause symptoms similarly burdensome regardless of age at menopause onset
4
Kate McLean, MD, MPH, explains microbial subtypes within bacterial vaginosis
5